Adaptimmune's Series A Round

Adaptimmune raised a round of funding on September 25, 2014.

Adaptimmune is focused on the use of T cell therapy with engineered T cell receptors to treat cancer and infectious disease. Established in July 2008 with a research base in Oxford, UK and a clinical …

Articles about Adaptimmune's Series A Round: